Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an announcement.

Hansoh Pharmaceutical Group announced that its innovative lung cancer drug Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, has received European Union approval as a monotherapy. The authorization covers first-line treatment of adults with advanced EGFR-mutated non-small cell lung cancer, as well as patients with advanced EGFR T790M mutation-positive disease, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.

The EU approval significantly extends the global reach of Aumolertinib, which already holds multiple indications in China and marketing authorization in the U.K. This milestone strengthens Hansoh’s position in the competitive global oncology market and underscores its transition from a domestic innovator to an international player in targeted cancer therapies, with potential benefits for its growth prospects and international partnerships.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on innovative therapies, particularly in oncology. Its portfolio includes Aumolertinib Mesylate Tablets, a third-generation EGFR tyrosine kinase inhibitor used to treat various forms and stages of non-small cell lung cancer, reflecting a strategic emphasis on targeted cancer treatments in both domestic and international markets.

Average Trading Volume: 8,280,646

Technical Sentiment Signal: Buy

Current Market Cap: HK$223.4B

See more insights into 3692 stock on TipRanks’ Stock Analysis page.